NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy.
Simone Dal BelloSimone LorenzutEmma SaccomanoYan TereshkoGian Luigi GigliCarlo Ennio PucilloMariarosaria ValentePublished in: Pharmaceuticals (Basel, Switzerland) (2024)
Lower percentage levels of NK cells 3 months after anti-CD20 infusion correlate with the presence of disease activity 6 months after therapy, confirming a possible protective role of NK cells in MS.
Keyphrases
- nk cells
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- multiple sclerosis
- mass spectrometry
- diffuse large b cell lymphoma
- low dose
- ms ms
- stem cells
- bone marrow
- hodgkin lymphoma
- cell therapy
- chronic lymphocytic leukemia
- mesenchymal stem cells
- replacement therapy